Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elio Adib

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Urologic Oncology|January 13, 2022
Prevalence of pathogenic germline cancer risk variants in testicular cancer patients: Identifying high risk groupsChethan Ramamurthy, Amin H Nassar, Sarah Abou Alaiwi, et al.
Genome Medicine|April 16, 2022
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histologyElio Adib, Amin H Nassar, Sarah Abou Alaiwi, et al.
BJUI Compass|February 28, 2022
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinomaElio Adib, Talal El Zarif, Rohit K Jain, et al.
Molecular Cancer Therapeutics|June 10, 2021
Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting AgentEddy S Yang, Amin H Nassar, Elio Adib, et al.
Clinical Genitourinary Cancer|September 10, 2021
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotinCatherine Curran, Elio Adib, Vera Kazakova, et al.
JTO Clinical and Research Reports|April 2, 2025
PD-L1, Tumor Mutational Burden, and Outcomes in NSCLC With Brain Metastases: A Brief ReportElio Adib, Amin H Nassar, Elias Bou Farhat, et al.
Clinical Genitourinary Cancer|May 25, 2022
Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitorsPier Vitale Nuzzo, Elio Adib, Nicole Weise, et al.
British Journal of Cancer|December 24, 2021
CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancerElio Adib, Talal El Zarif, Amin H Nassar, et al.
Journal for Immunotherapy of Cancer|November 2, 2021
Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancerShaoming Zhu, A-Hong Ma, Zheng Zhu, et al.
JAMA Oncology|February 12, 2026
Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung CancerMehrdad Rakaee, Amin H Nassar, Masoud Tafavvoghi, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Urologic Oncology|January 13, 2022
Prevalence of pathogenic germline cancer risk variants in testicular cancer patients: Identifying high risk groupsChethan Ramamurthy, Amin H Nassar, Sarah Abou Alaiwi, et al.
Genome Medicine|April 16, 2022
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histologyElio Adib, Amin H Nassar, Sarah Abou Alaiwi, et al.
BJUI Compass|February 28, 2022
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinomaElio Adib, Talal El Zarif, Rohit K Jain, et al.
Molecular Cancer Therapeutics|June 10, 2021
Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting AgentEddy S Yang, Amin H Nassar, Elio Adib, et al.
Clinical Genitourinary Cancer|September 10, 2021
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotinCatherine Curran, Elio Adib, Vera Kazakova, et al.
JTO Clinical and Research Reports|April 2, 2025
PD-L1, Tumor Mutational Burden, and Outcomes in NSCLC With Brain Metastases: A Brief ReportElio Adib, Amin H Nassar, Elias Bou Farhat, et al.
Clinical Genitourinary Cancer|May 25, 2022
Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitorsPier Vitale Nuzzo, Elio Adib, Nicole Weise, et al.
British Journal of Cancer|December 24, 2021
CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancerElio Adib, Talal El Zarif, Amin H Nassar, et al.
Journal for Immunotherapy of Cancer|November 2, 2021
Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancerShaoming Zhu, A-Hong Ma, Zheng Zhu, et al.
JAMA Oncology|February 12, 2026
Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung CancerMehrdad Rakaee, Amin H Nassar, Masoud Tafavvoghi, et al.
Pageof 5